Observational studyFrontiers in immunology2025

Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study.

Xichao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.